# Golimumab

## Simponi inj 50mg/0.5mL

| TAH Drug Code      | [ISIM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISIM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. **Rheumatoid Arthritis** In combination with methotrexate， indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis. 2. **Psoriatic Arthritis** Used alone or in combination with methotrexate， indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs). 3. **Ankylosing Spondylitis** Indicated for the treatment of adult patients with active ankylosing spondylitis. 4. **Ulcerative Colitis** Indicated for the treatment of adult patients with moderate to severe active ulcerative colitis who have had an inadequate response to， or are intolerant to， or have contraindications to traditional treatments such as corticosteroids， 6-mercaptopurine (6-MP)， or azathioprine (AZA). 5. **Non-radiographic Axial Spondyloarthritis (nr-axSpA)** Indicated for the treatment of adult patients with severe active non-radiographic axial spondyloarthritis who meet all of the following criteria: (1) Inadequate response to or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs). (2) Elevated C-reactive protein (CRP) levels. (3) MRI evidence of inflammatory changes. (4) HLA-B27 positive. |
| Dosing             | SC， rheumatoid arthritis， psoriatic arthritis and ankylosing spondylitis 50 mg once a month. Moderate to severe active ulcerative colitis( body weight<80 kg) 200 mg at week 0， then 100 mg at week 2， followed by 50-100 mg every 4 weeks.( body weight > or = 80kg) 200 mg at week 0， then 100 mg at week 2， followed by 100 mg every 4 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Canadian labeling: Hypersensitivity to golimumab， latex， or any other component of formulation or packaging; patients with severe infections (eg， sepsis， tuberculosis， opportunistic infections); moderate or severe heart failure (NYHA class III/IV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Serious infections， malignancies， autoimmune disorders & autoantibodies， inj site reactions， new onset & exacerbations of psoriasis， immunogenicity， upper resp tract infection， nasopharyngitis， sepsis， increased ALT & AST; HTN， bronchitis， dizziness， sinusitis， flu， pharyngitis， rhinitis， pyrexia， oral herpes， paraesthesia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/golimumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

